Marc Arbyn
"M Arbyn has diplomas of MD, MSc, Dr in tropical medicine and PhD in medicine & health Science. After a career in Africa with Médecins Sans Frontières, he got involved in cancer research in Europe. MA coordinated the evaluation of new screening methods in the framework of the European Network of Cervical Cancer Screening and is editor- of the European Guidelines for Cervical Cancer Screening and associated Supplements on HPV screening. His main activity deals with systematic reviews, Cochrane reviews and meta-analyses regarding prevention and treatment of HPV-related cancers and their precursors (cervical cancer screening, diagnosis and treatment of cervical precancer, anal cancer and oropharyngeal cancer...MA is principle investigator of the VALGENT (VALidation of hpv GENotyping Tests) and VALHUDES (VALidation of HUman papillomavirus assays and collection DEvices for HPV testing on Self-samples and urine samples) studies. These are independent researcher-induced protocols used for HPV test comparison and validation on clinician-collected cervical samples, vaginal self-samples and urine. MA is currently updating methods for test validation in collaboration with an international network of experts involving clinical epidemiologist and virologists. MA is coordinator of the Unit of Cancer Epidemiology, which is part of the Belgian Cancer Centre at the Scientific Institute of Public Health in Brussels. He was member of the Board of Directors of the International Papillomavirus Society (IPV) from 2012 to 2018 and congress president of EUROGIN 2018 (Lisbon, Portugal)." [1]
He was the lead author of a 2018 article along with Sara B Smith, Sarah Temin, Farhana Sultana, and Philip Castle. The "review was supported by Global Coalition Against Cervical Cancer (New York, NY, USA) through a grant by the US Centers for Disease Control and Prevention through its cooperative agreement with the National Network of Public Health Institutes and subaward to GC3". "SS was supported in part by unrestricted educational grants to the Global Coalition Against Cervical Cancer from Rovers, BD, QIAGEN, and Roche; a contract from Chengdu Genegle Biotechnology Co, Ltd; and has received cervical screening tests and diagnostics at a reduced or no cost for research from BD, Hologic, Rovers, Arbor Vita Corp, and Trovagene. PC has received cervical screening tests and diagnostics at a reduced or no cost for research from Roche, BD, Cepheid, and Arbor Vita Corporation."[1]
